Rhythm Pharmaceuticals, INC 8-K filings

Rhythm Pharmaceuticals announced its first quarter 2024 financial results, highlighted by $26 million in net revenue from IMCIVREE sales and a $150 million convertible preferred stock financing.

Rhythm Pharmaceuticals closed a $150 million investment through the issuance of Series A Convertible Preferred Stock, granting investors certain registration rights.

Rhythm Pharmaceuticals has secured a $150 million investment through the sale of convertible preferred stock to fund its operations into 2026.

Rhythm Pharmaceuticals has increased its at-the-market offering capacity to $200 million through an amendment to its sales agreement with Cowen and Company.

Rhythm Pharmaceuticals reported a net revenue of $24.2 million for Q4 2023 and $77.4 million for the full year, alongside completing enrollment in a pivotal Phase 3 trial for setmelanotide in hypothalamic obesity.